Save time and jump to the most important pieces.
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
DEFR14A - Silo Pharma, Inc. (0001514183) (Filer)
SCHEDULE 13G - Silo Pharma, Inc. (0001514183) (Subject)
10-Q - Silo Pharma, Inc. (0001514183) (Filer)
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded down 0.91% to 40,293.66 while the NASDAQ fell 0.70% to 17,746.27. The S&P 500 also fell, dropping, 0.61% to 5,510.84. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsHeath care shares jumped by 0.5% on Thursday. In trading on Thursday, information technology shares fell by 1%. Top Headline Netflix Inc. (NASDAQ:NFLX) posted better-than-expected earnings and sales results for its second quarter, after the closing bell on Thursday. The company ende
Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points on Friday. The Dow traded down 0.78% to 40,347.51 while the NASDAQ fell 0.29% to 17,819.43. The S&P 500 also fell, dropping, 0.29% to 5,528.67. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsCommunication services shares jumped by 0.7% on Thursday. In trading on Thursday, materials shares fell by 1%. Top Headline Schlumberger N.V. (NYSE:SLB) reported better-than-expected second-quarter results. The company said revenue increased 13% year-over-year to $9.139 billion, beating
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. These tests were conducted under the Company's current development agreement with Sever Pharma Solutions. Previously, Silo disclosed that Sever
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stre